ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Saw Palmetto and BPH - Past, Present, and Future
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 216829" data-attributes="member: 13851"><p><strong><em>post #8</em></strong></p><p>[URL unfurl="true"]https://www.excelmale.com/forum/threads/prostate-supplements.24649/#post-215163[/URL]</p><p></p><p></p><p><strong>5.2.5 Plant extracts - phytotherapy</strong></p><p><strong></strong></p><p><strong>Potential mechanism of action:</strong> <em>Herbal drug preparations are made of roots, seeds, pollen, bark, or fruits. There are single plant preparations (mono-preparations) and preparations combining two or more plants in one pill (combination preparations) [216].</em></p><p><em></em></p><p><em><strong>Possible relevant compounds include phytosterols, ß-sitosterol, fatty acids, and lectins [216]. <u>In vitro, plant extracts can have anti-inflammatory, anti-androgenic and oestrogenic effects; decrease sexual hormone-binding globulin; inhibit aromatase, lipoxygenase, growth factor-stimulated proliferation of prostatic cells, α-adrenoceptors, 5 α-reductase, muscarinic cholinoceptors, dihydropyridine receptors, and vanilloid receptors; and neutralize free radicals</u> [216-218]. <u>The in vivo effects of these compounds are uncertain, and the precise mechanisms of plant extracts remain unclear</u>.</strong></em></p><p></p><p></p><p><strong>Efficacy: <em>The extracts of the same plant produced by different companies do not necessarily have the same biological or clinical effects; therefore, the effects of one brand cannot be extrapolated to others [219]. In addition, batches from the same producer may contain different concentrations of active ingredients [220]. </em></strong><em>A review of recent extraction techniques and their impact on the composition/biological activity of available Serenoa repens based products showed that results from different clinical trials must be compared strictly according to the same validated extraction technique and/or content of active compounds [221], as the pharmacokinetic properties of the different preparations can vary significantly.</em></p><p></p><p><strong><em>Heterogeneity and a limited regulatory framework characterize the current status of phytotherapeutic agents.</em> </strong><em>The European Medicines Agency (EMA) has developed the Committee on Herbal Medicinal Products (HMPC).</em> <strong><em>European Union (EU) herbal monographs contain the HMPC’s scientific opinion on safety and efficacy data about herbal substances and their preparations intended for medicinal use.</em></strong> <strong><em>The HMPC evaluates all available information, including non-clinical and clinical data, whilst also documenting long-standing use and experience in the EU.</em></strong></p><p><strong></strong></p><p><strong>European Union monographs are divided into two sections: <em>a)</em></strong><em> <strong><u>Well established use (marketing authorization)</u>:</strong> when an active ingredient of medicine has been used for more than ten years and its efficacy and safety have been well established (including a review of the relevant literature); and <strong>b) <u>Traditional use (simplified registration)</u>:</strong> for herbal medicinal products which do not fulfill the requirements for marketing authorization, but there is </em><strong><em>sufficient safety data and plausible efficacy on the basis of long-standing use and experience. Table 1 lists the available EU monographs for herbal medicinal products.</em></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Table 2: European Union monographs for herbal medicinal products</strong></p><p><strong>[ATTACH=full]19541[/ATTACH]</strong></p><p><strong></strong></p><p><strong>Panel interpretation:</strong> <strong><em><u>Only hexane extracted Serenoa reprens have been recommended for well-established use by the HMPC</u>.</em></strong><em> A detailed scoping search covering the timeframe between the search cut-off date of the EU monograph and April 2020 will be conducted for the update of the 2021 edition of the Guidelines. Following this, a specific recommendation on phytotherapy will be given.</em></p></blockquote><p></p>
[QUOTE="madman, post: 216829, member: 13851"] [B][I]post #8[/I][/B] [URL unfurl="true"]https://www.excelmale.com/forum/threads/prostate-supplements.24649/#post-215163[/URL] [B]5.2.5 Plant extracts - phytotherapy Potential mechanism of action:[/B] [I]Herbal drug preparations are made of roots, seeds, pollen, bark, or fruits. There are single plant preparations (mono-preparations) and preparations combining two or more plants in one pill (combination preparations) [216]. [B]Possible relevant compounds include phytosterols, ß-sitosterol, fatty acids, and lectins [216]. [U]In vitro, plant extracts can have anti-inflammatory, anti-androgenic and oestrogenic effects; decrease sexual hormone-binding globulin; inhibit aromatase, lipoxygenase, growth factor-stimulated proliferation of prostatic cells, α-adrenoceptors, 5 α-reductase, muscarinic cholinoceptors, dihydropyridine receptors, and vanilloid receptors; and neutralize free radicals[/U] [216-218]. [U]The in vivo effects of these compounds are uncertain, and the precise mechanisms of plant extracts remain unclear[/U].[/B][/I] [B]Efficacy: [I]The extracts of the same plant produced by different companies do not necessarily have the same biological or clinical effects; therefore, the effects of one brand cannot be extrapolated to others [219]. In addition, batches from the same producer may contain different concentrations of active ingredients [220]. [/I][/B][I]A review of recent extraction techniques and their impact on the composition/biological activity of available Serenoa repens based products showed that results from different clinical trials must be compared strictly according to the same validated extraction technique and/or content of active compounds [221], as the pharmacokinetic properties of the different preparations can vary significantly.[/I] [B][I]Heterogeneity and a limited regulatory framework characterize the current status of phytotherapeutic agents.[/I] [/B][I]The European Medicines Agency (EMA) has developed the Committee on Herbal Medicinal Products (HMPC).[/I] [B][I]European Union (EU) herbal monographs contain the HMPC’s scientific opinion on safety and efficacy data about herbal substances and their preparations intended for medicinal use.[/I][/B] [B][I]The HMPC evaluates all available information, including non-clinical and clinical data, whilst also documenting long-standing use and experience in the EU.[/I] European Union monographs are divided into two sections: [I]a)[/I][/B][I] [B][U]Well established use (marketing authorization)[/U]:[/B] when an active ingredient of medicine has been used for more than ten years and its efficacy and safety have been well established (including a review of the relevant literature); and [B]b) [U]Traditional use (simplified registration)[/U]:[/B] for herbal medicinal products which do not fulfill the requirements for marketing authorization, but there is [/I][B][I]sufficient safety data and plausible efficacy on the basis of long-standing use and experience. Table 1 lists the available EU monographs for herbal medicinal products.[/I] Table 2: European Union monographs for herbal medicinal products [ATTACH type="full"]19541[/ATTACH] Panel interpretation:[/B] [B][I][U]Only hexane extracted Serenoa reprens have been recommended for well-established use by the HMPC[/U].[/I][/B][I] A detailed scoping search covering the timeframe between the search cut-off date of the EU monograph and April 2020 will be conducted for the update of the 2021 edition of the Guidelines. Following this, a specific recommendation on phytotherapy will be given.[/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Saw Palmetto and BPH - Past, Present, and Future
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top